Operative management of trigeminal schwannomas: based on a modified classification in a study of 93 cases.

BACKGROUND: Advances in microscopic and endoscopic surgical techniques have outpaced traditional classification and transcranial surgical strategies, especially with reference to the treatment of trigeminal schwannomas (TSs). A modified TS classification is proposed and appropriate surgical strategies are discussed. METHODS: The cases of 93 patients who underwent surgical treatment in Beijing Tiantan Hospital in the previous 6 years were analyzed retrospectively, and a literature review was conducted. RESULTS: Classification is based on surgical direction. Tumors were classified as follows: type A, backward orientation, located in the orbit or orbit and middle cranial fossa (8 cases, 8.6%); type B, upward orientation, located in the pterygopalatine fossa, infratemporal fossa or pterygopalatine fossa, infratemporal fossa, and middle cranial fossa (23 cases, 24.7%); type C, forward and backward orientations, located in the middle cranial fossa, posterior cranial fossa or both (58 cases, 62.4%); and type D, located in multiple regions (4 cases, 4.3%). 91.40% of patients underwent gross total resection (GTR) with 29 cases receiving endoscopic resection of whom 93.10% (27/29) experienced GTR. CONCLUSION: The 93 cases were satisfactorily divided into four types, according to tumor location and surgical orientation, enabling safe and effective removal by appropriate surgery.

[Low-intensity extracorporeal shockwave therapy improves symptoms of erectile dysfunction: A preliminary study].

OBJECTIVE: To verify the effect and safety of low-intensity extracorporeal shockwave therapy (Li-ESWT) in improving the symptoms of ED, and provide some reference for further related large-scale clinical trials. METHODS: Twenty-six patients diagnosed with ED received Li-ESWT with an energy of 0.09 mJ/mm2 for 20 minutes once a week for 6 four-week courses. Before and at 3, 6, 9, and 12 months after treatment, we obtained the IIEF-5 and Erectile Hardness Scale (EHS) scores of the patients using questionnaires, recorded the incidence of treatment-related adverse reactions, compared the erectile function of the patients before and after treatment, and evaluated the effect and safety of Li-ESWT in improving ED-related symptoms. RESULTS: Compared with the baseline, the IIEF-5 scores of the patients were significantly increased (P < 0.01) while the EHS scores slightly increased at 3 months after Li-ESWT treatment (P > 0.05), both IIEF-5 and EHS scores were dramatically increased at 6 months (P < 0.01), and both significantly higher than at 3 months. At 9 months, EHS scores remained remarkably higher than the baseline (P < 0.01) although IIEF-5 scores slightly lower than at 6 months. At 12 months, however, IIEF-5 scores decreased, though still significantly higher than the baseline (P < 0.01), and EHS scores became lower than at 6 and 9 months (P < 0.05) but still markedly higher than before treatment (P < 0.05). Adverse reactions observed during the intervention mainly included pruritus (4.35%), pain (2.90%), paresthesia (2.17%), and petechiae/ecchymosis (2.90%). CONCLUSION: Li-ESWT can increase the IIEF-5 and EHS scores and improve the clinical symptoms of ED patients, with a low incidence of adverse reactions during the treatment.

Angiotensin(1-7) Improves Islet Function in Diabetes Through Reducing JNK/Caspase-3 Signaling.

The aim of this study is to investigate whether Angiotensin (1-7), the physiological antagonist of Angiotensin II (AngII), has antidiabetic activity and the possible mechanism. Male Wistar rats were randomly divided into 3 groups: control group fed the normal diet, DM group fed high-fat diet and injected with STZ, and Angiotensin (1-7) group receiving injection of STZ followed by Angiotensin (1-7) treatment. Serum Ang II, fasting blood glucose, insulin, HOMA-IR, and HOMA-beta were determined in control, diabetes and Angiotensin (1-7) groups. The increased AngII and insulin resistance in diabetes group were accompanied by changes in islet histopathology. However, Angiotensin (1-7) improved the islet function and histopathology in diabetes without affecting the level of AngII. Western blot confirmed that Angiotensin (1-7) decreased the cleaved caspase 3 levels in pancreas of DM. The increased expression of JNK, Bax, and Bcl2 genes under diabetic conditions were partially reversed after Angiotensin (1-7) administration in pancreas. Immunofluorescence analysis showed that p-JNK was markedly increased in islet of DM rats, which was markedly alleviated after Angiotensin (1-7) treatment. Furthermore, Angiotensin (1-7) reversed high glucose(HG) induced mitochondrial apoptosis augments. Finally, Angiotensin (1-7) attenuated the apoptosis of INS-1 cells through reducing JNK activation in diabetes, which was blocked by anisomycin (a potent agonist of JNK). Our findings provide supporting evidence that Angiotensin (1-7) improved the islet beta-cells apoptosis by JNK-mediated mitochondrial dysfunction, which might be a novel target for the treatment and prevention of beta-cells dysfunction in DM.

[Prostate-specific membrane antigen-targeted drug delivery system for prostate cancer].

Prostate cancer (PCa) is a most common malignancy in the genitourinary system, which imposes a huge burden on the patients and society. Various traditional medication methods fail to achieve satisfactory effects, and therefore it is imperative to develop innovative and effective routes of administration. Drug delivery systems have the characteristics of both delivery and controlled release and are widely used clinically. Prostate-specific membrane antigen (PSMA) is one of the most characteristic and highly selective biomarkers of PCa with a good PCa-targetability. Many drug delivery systems targeting PSMA have been explored, including drug-ligand conjugates and nano-drug delivery systems (polymer nanoparticles, inorganic nanoparticles, liposomes, and biological nanoparticles, etc.). This article reviews the recent studies on the role of the PSMA-targeting drug delivery system in PCa, in order to provide some reference for the precise and effective treatment of the malignancy.

LncRNA LncHrt preserves cardiac metabolic homeostasis and heart function by modulating the LKB1-AMPK signaling pathway.

Metabolic modulation is a promising therapeutic approach to prevent adverse remodeling of the ischemic heart. Because little is known about the involvement of long non-coding RNAs (lncRNAs) in regulating cardiac metabolism, we used unbiased transcriptome profiling in a mouse model of myocardial infarction (MI). We identified a novel cardiomyocyte-enriched lncRNA, called LncHrt, which regulates metabolism and the pathophysiological processes that lead to heart failure. AAV-based LncHrt overexpression protects the heart from MI as demonstrated by improved contractile function, preserved metabolic homeostasis, and attenuated maladaptive remodeling responses. RNA-pull down followed by mass spectrometry and RNA immunoprecipitation (RIP) identified SIRT2 as a LncHrt-interacting protein involved in cardiac metabolic regulation. Mechanistically, we established that LncHrt interacts with SIRT2 to preserve SIRT2 deacetylase activity by interfering with the CDK5 and SIRT2 interaction. This increases downstream LKB1-AMPK kinase signaling, which ameliorates functional and metabolic deficits. Importantly, we found the expression of the human homolog of mouse LncHrt was decreased in patients with dilated cardiomyopathy. Together, these studies identify LncHrt as a cardiac metabolic regulator that plays an essential role in preserving heart function by regulating downstream metabolic signaling pathways. Consequently, LncHrt is a potentially novel RNA-based therapeutic target for ischemic heart disease.

Role of decompressive craniectomy in the management of poor-grade aneurysmal subarachnoid hemorrhage: short- and long-term outcomes in a matched-pair study.

OBJECTIVE: To evaluate the short- and long-term therapeutic effect and possibility of decompressive craniectomy (DC) for patients with poor-grade aneurysmal subarachnoid hemorrhage (aSAH). METHODS: Patients suffering from aSAH (Hunt-Hess grades IV, V) who underwent DC from January 2008 to April 2016 were enrolled in this study, and a sample-matched control group was set up. Information regarding participants' demography, clinical characteristics, and neuroimaging findings was systematically established. The outcome of a 6-month to 3-year follow-up was assessed according to the Glasgow outcome scale (GOS), modified Rankin Scale (mRS) and Barthel Index (BI). RESULTS: Patients who had DC (21) experienced a statistically significant decrease in short-term mortality compared with those without DC (24, p < 0.05) and showed a decrease in intracranial pressure (ICP) after surgery. However, there was no significant difference in the long-term assessment (GOS/mRS/BI) between the two groups. CONCLUSIONS: Some critical patients who have refractory ICP after poor-grade aSAH would benefit from DC for prolonging life in the short term if performed early. Nevertheless, the overall outcome for the long term remains disappointing, larger and longer prospective studies are urgently needed to investigate this issue.

Growth differentiation factor 11 promotes differentiation of MSCs into endothelial-like cells for angiogenesis.

Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-ß super family. It has multiple effects on development, physiology and diseases. However, the role of GDF11 in the development of mesenchymal stem cells (MSCs) is not clear. To explore the effects of GDF11 on the differentiation and pro-angiogenic activities of MSCs, mouse bone marrow-derived MSCs were engineered to overexpress GDF11 (MSCGDF11 ) and their capacity for differentiation and paracrine actions were examined both in vitro and in vivo. Expression of endothelial markers CD31 and VEGFR2 at the levels of both mRNA and protein was significantly higher in MSCGDF11 than control MSCs (MSCVector ) during differentiation. More tube formation was observed in MSCGDF11 as compared with controls. In an in vivo angiogenesis assay with Matrigel plug, MSCGDF11 showed more differentiation into CD31+ endothelial-like cells and better pro-angiogenic activity as compared with MSCVector . Mechanistically, the enhanced differentiation by GDF11 involved activation of extracellular-signal-related kinase (ERK) and eukaryotic translation initiation factor 4E (EIF4E). Inhibition of either TGF-ß receptor or ERK diminished the effect of GDF11 on MSC differentiation. In summary, our study unveils the function of GDF11 in the pro-angiogenic activities of MSCs by enhancing endothelial differentiation via the TGFß-R/ERK/EIF4E pathway.

Synthesis and molecular simulation study of furoic peptidomimetic derivatives as potent aminopeptodase N inhibitors.

The aminopeptidase N (APN) plays a critical role in angiogenesis and is over-expressed in tumor cells. In this paper, we report the synthesis and enzyme inhibition assay of furoic peptidomimetic compounds. These new compounds exhibit potent inhibitory ability toward APN with IC50 values lying in the micromolar level. The binding mode of inhibitors in APN active site was explained by a molecular simulation study. These data reveal that ligand coordinating with the catalytic Zn-ion is very important for inhibitory activities.

A refined surgical treatment modality for bromhidrosis: Subcutaneous scissor with micropore.

Axillary bromhidrosis has a strong negative effect on one's social life. A high success rate and few complications are criteria for a surgical treatment. The objective of this study was to evaluate a new surgical treatment modality for bromhidrosis: subcutaneous scissor with micropore. Twenty patients with bromhidrosis were treated. Patients were placed in a supine position with their treated arms abducted to 110°. After injection of 60 mL of tumescent solution into each axilla, one small incision was made at the middle axillary of the hair-bearing area. The whole hair-bearing skin was undermined at the level of the superficial fat to obtain adequate skin eversion. The flaps were everted to offer full exposure of the apocrine glands, and meticulous excision of each gland was performed. Both sides were punctured with scalpel. The micropore was used for drainage, and whose width was just 3 mm. Finally, the incisions were re-approximated, and bulky compressive dressings were applied to the area for 72 hours. Of the 40 axillae (20 patients), 34 (85.0%) showed excellent results, and six (15.0%) had good results. Malodor was significantly decreased. There were no serious complications. This technique can produce excellent results with a lower complication rate than most other surgical modalities and can be performed without costly equipment.

The discovery of the genus Spasskia Belokobylskij, 1989 (Hymenoptera: Braconidae) in China, with description of a new species.

The genus Spasskia Belokobylskij, 1989 (Hymenoptera: Braconidae: Helconinae) is reported for the first time from China. Two species, namely Spasskia brevicarinata Yan et Chen sp. n.and Spasskia indica Singh, Belokobylskij et Chauhan, 2005 are described and illustrated. A key to the species of this genus is updated to include the new species.

The subgenus Choeras Mason, 1981 of genus Apanteles Foerster, 1862 (Hymenoptera, Braconidae, Microgastrinae) from China, with descriptions of eighteen new species.

The subgenus Choeras Mason, 1981 of genus Apanteles Foerster, 1862 (Hymenoptera, Braconidae, Microgastrinae) from China is revised with 18 new species described and illustrated, and one known species redescribed. A key to the Chinese species of this subgenus is provided.

The genus Ademon Haliday (Hymenoptera: Braconidae: Opiinae) from China, with descriptions of two new species.

The species of Ademon Haliday (Braconidae, Opiiinae) from China are studied. Two new species are described: A. lechrilophodes sp. nov. and A. xuthus sp. nov., and a key to the identification of Old World Ademon is provided.

The grandiculus- and metacarpalis-group of the genus Apanteles Foerster, 1862 (Hymenoptera, Braconidae, Microgastrinae) from China, with descriptions of eight new species.

Two species groups (the grandiculus- and the metacarpalis-group) of genus Apanteles Foerster (Hymenoptera, Braconidae, Microgastrinae) from China are revised and keyed, with eight new species, namely, A. muticiculus Liu & Chen, sp. n., A. parvus Liu & Chen, sp. n. and A. flavicapus Liu & Chen, sp. n. of the grandiculus-group; A. transtergum Liu & Chen, sp. n., A. malleus Liu & Chen, sp. n., A. dumosus Liu & Chen, sp. n. A. cosmopterygivorus Liu & Chen, sp. n. and A. incurvus Liu & Chen, sp. n. of the metacarpalis-group, and two newly recorded species of the metacarpalis-group described and illustrated. Keys to the Chinese species of these two species-groups are provided.

Leukocyte telomere length and sarcopenia-related traits: A bidirectional Mendelian randomization study.

Accumulating evidence indicated that leukocyte telomere length (LTL) was related to sarcopenia. However, it is still not clear whether the association of changes in LTL with sarcopenia is likely to be causal, or could be explained by reverse causality. Thus, we carried on bidirectional Mendelian randomization (MR) and multivariable MR analyses to identify the causal relationship between LTL and sarcopenia-related traits. Summary-level data and independent variants used as instruments came from large genome-wide association studies of LTL (472,174 participants), appendicular lean mass (450,243 participants), low grip strength (256,523 participants), and walking pace (450,967 participants). We identified suggestive association of longer LTL with larger appendicular lean mass [odds ratio (OR) = 1.053; 95% confidence interval (CI), 1.009-1.099; P = 0.018], and causal association of longer LTL with a lower risk of low grip strength (OR = 0.915; 95% CI, 0.860-0.974; P = 0.005). In the reverse MR analysis, we also observed a positive causal association between walking pace and LTL (OR = 1.252; 95% CI, 1.121-1.397; P < 0.001). Similar results can be repeated in sensitivity analyses. While in the multivariable MR analysis, the estimate of the impact of walking pace on LTL underwent a transformation after adjusting for T2DM (OR = 1.141; 95%CI: 0.989-1.317; P = 0.070). The current MR analysis supported a causal relationship between shorter telomere length and both low muscle mass and strength. Additionally, walking pace may affect LTL through T2DM.

Efficacy and safety of bevacizumab in neoadjuvant and concurrent chemoradiotherapy for refractory cervical cancer patients.

A platinum-based concurrent chemoradiotherapy (CCRT) is the standard treatment for refractory cervical cancer (CC). However, the recurrence of disease and the occurrence of metastasis remain prevalent. We observed the long-term efficacy and safety of bevacizumab combined with neoadjuvant chemotherapy (NACT) and CCRT in refractory CC. A total of 62 patients with refractory CC were enrolled in this study from January 2016 to December 2019. The NACT regimen included bevacizumab (7.5 mg/kg), docetaxel (75 mg/m2), and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. The CCRT regimen included bevacizumab (7.5 mg/kg) and cisplatin (75 mg/m2), administered tri-weekly for 2 cycles. A dose of 45-50 Gy was prescribed for external beam radiotherapy (EBRT), while 30-35 Gy in 4-5 fractions was prescribed for brachytherapy (BT). Among the patients, 21 patients (33.9%) were at stages IIB-IIIB, 8 patients (12.9%) were at stage IIIC1, 19 patients (30.6%) were at stage IIIC2, and 14 patients (22.6%) were at stage IVB. Pelvic, para-aortic, supraclavicular, and inguinal lymph node metastases were discovered in 41 patients (66.1%). The median follow-up was 49.8 months (12.3-82.7 months). The median tumor volumes pre-treatment, after NACT, and before BT were 84.64 ± 53.15 cm3, 1.64 ± 13.15 cm3, and 0 ± 1.5 cm3, respectively. Complete clinical response (cCR) rates after NACT and EBRT were 35.5% and 66.1%, respectively. Four years after the diagnosis, the overall survival (OS) rate was 78.6%, the local region-free survival (LRFS) rate was 91.3%, the disease-free survival (DFS) rate was 70.6%, and the distant metastasis-free survival (DMFS) rate was 81.4%. A total of 29 patients (46.8%) experienced grade 3/4 hematological toxicity, 3 patients (4.8%) experienced grade 3 gastrointestinal toxicities, and none experienced grade 5 adverse events. Bevacizumab combined with NACT and CCRT significantly improved cCR and OS in refractory CC with acceptable toxicity.

Dryinidae of the Oriental region (Hymenoptera: Chrysidoidea).

An updated revision of Oriental Dryinidae is presented. Seven subfamilies, 20 genera and 368 species are treated. Eight new species are described: Aphelopus zonalis Xu, Olmi & He, sp. nov. (China, Hainan); Anteon zoilum Xu, Olmi & He, sp. nov. (China, Yunnan), Anteon zonarium Xu, Olmi & He, sp. nov. (China, Yunnan), Anteon zopyrum Xu, Olmi & He, sp. nov. (China, Xizang), Anteon zoroastrum Xu, Olmi & He, sp. nov. (Malaysia, Malaya), Esagonatopus sinensis Xu, Olmi & He, sp. nov. (China, Yunnan), Gonatopus yunnanensis Xu, Olmi & He, sp. nov. (China, Yunnan); Ponomarenkoa ellenbergeri Olmi, Xu & He, sp. nov. (Myanmar amber). Descriptions, geographic distribution, known hosts, natural en-emies and type material of each species are presented, together with illustrations of the main morphological characters and keys to the subfamilies, genera and species. Complete lists of references concerning the Oriental Dryinidae and their hosts are given. New synonymies are proposed for Aphelopus albiclypeus Xu, He & Olmi, 1999 (=A. exnotaulices He & Xu, 2002, syn. nov.), A. orientalis Olmi, 1984 (=A. albopictoides Xu & He, 1999, syn. nov.), A. taiwanensis Olmi, 1991 (=A. compresssus Xu & Yao, 1997, syn. nov.), A. niger Xu & He, 1999 (=A. nigricornis Xu, He & Olmi, 1999, syn. nov.), A. penanganus Olmi, 1984 (=A.olmii He & Xu, 2002, syn. nov.), Anteon cacumen Xu & He, 1997 (=A. longwangshanense Xu & He, 1997, syn. nov.), A. hilare Olmi, 1984 (=A. corax Olmi, 1984, syn. nov., =A. javanum Olmi, 1984, syn. nov., =A. serratum Xu & He, 1999, syn. nov.), A. lankanum Olmi, 1984 (=A. planum Xu & He, 1999, syn. nov.), A. munitum Olmi, 1984 (=A. bauense Olmi, 1984, syn. nov.), A. parapriscum Olmi, 1991 (=A. alpinum He & Xu, 2002, syn. nov.), A. peterseni Olmi, 1984 (=A. scrupulosum He & Xu, 2002, syn. nov.), A. yuani Xu, He & Olmi, 1998 (=A. yuae He & Xu, 2002, syn. nov.), Lonchodryinus bimaculatus Xu & He, 1994 (=L. niger He & Xu, 2002, syn. nov.), L. ruficornis (Dalman, 1818) (=L. melaphelus Xu & He, 1994, syn. nov.), Dryinus indicus (Kieffer, 1914) (=Chlorodryinus koreanus Móczár, 1983, syn. nov., =Dryinus masneri Olmi, 2009, syn. nov.), D. stantoni Ashmead, 1904 (=D. undatomarginis Xu & He, 1998, syn. nov., =D. wuyishanensis He & Xu, 2002, syn. nov.), Adryinus jini Xu & Yang, 1995 (=A. platycornis Xu & He, 1995, syn. nov.), Gonatopus nigricans (R. Perkins, 1905 (=G. fulgori Nakagawa, 1906, syn. nov., =G. insulanus He & Xu, 1998, syn. nov., Pseudogonatopus sogatea Rohwer, 1920, syn. nov.; P. pusanus Olmi, 1984, syn. nov.), G. nudus (R. Perkins, 1912) (=G. yangi He & Xu, 1998, syn. nov.), G. pedestris Dalman, 1818 (=Epigonatopus sakaii Esaki & Hashimoto, 1933, syn. nov.), G. rufoniger Olmi, 1993 (=Neodryinus hishimonovorus Xu & He, 1997, syn. nov.), G. schen-klingi Strand, 1913 (=G. euscelidivorus Xu & He, 1999, syn. nov.). New combinations are proposed for Deinodryinus con-strictus (Olmi, 1998), comb. nov. (from Anteon), Dryinus asiaticus (Olmi, 1984), comb. nov. (from Alphadryinus), D. barbarus (Olmi, 1984), comb. nov. (from Mesodryinus), Gonatopus bengalensis (Olmi, 1984), comb. nov. (from Agona-topoides ), G. bicuspis (Olmi, 1993), comb. nov. (from Pseudogonatopus), G. borneanus (Olmi, 1984), comb. nov. (from Agonatopoides ); G. indicus (Olmi, 1987), comb. nov. (from Donisthorpina), G. insularis (Olmi, 1984), comb. nov. (from Agonatopoides), G. lankae (Ponomarenko, 1981), comb. nov. (from Pseudogonatopus), G. malesiae (Olmi, 1984), comb. nov. (from Pseudogonatopus), G. nepalensis (Olmi, 1986), comb. nov. (from Pseudogonatopus), G. pajanensis (Olmi, 1989), comb. nov. (from Agonatopoides), G. pyrillae (Mani, 1942), comb. nov. (from Agonatopoides), G. sarawakensis (Olmi, 1984), comb. nov. (from Pseudogonatopus), G. validus (Olmi, 1984), comb. nov. (from Pseudogonatopus).

The discovery of genus Fredegunda Fitton, Shaw & Gauld in China, with description of a new species (Hymenoptera, Ichneumonidae, Pimplinae).

The genus Fredegunda Fitton, Shaw & Gauld (Ichneumonidae, Pimplinae) is newly reported both from China and the Oriental region. A new species, Fredegunda sinica sp. nov. from Fujian, China is described and illustrated. A key to the known species of Fredegunda is provided.

Two genera Foersteria Szépligeti, 1896 and Polydegmon Foerster, 1862 (Hymenoptera, Braconidae, Brachistinae) from China, with description of a new species.

The genera Foersteria Szépligeti, 1896 and Polydegmon Foerster, 1862 (Hymenoptera, Braconidae, Brachistinae) are recorded for the first time from China. A new species, Foersteria xinjiangensis Yan & Chen, sp. nov., is described and illustrated. A key to the Palaearctic species of Foersteria is given. In addition, Polydegmon sinuatus Foerster, 1862 is illustrated in detail for the first time.

Heterospilus Haliday, 1836 (Hymenoptera: Braconidae, Doryctinae) from China with a key to species.

The Chinese species of the genus Heterospilus Haliday, 1836 from the Parasitic Hymenoptera Collection of Zhejiang University were studied and thirty-four species are recognized, including 12 previously described species. Eighteen new species of this genus are described and illustrated: Heterospilus (Heterospilus) alternicoloratus sp. nov., H.(H.) balicyba sp. nov., H.(H.) chui sp. nov., H.(H.) curvisulcus sp. nov., H.(H.) densistriatus sp. nov., H.(H.) fujianensis sp. nov., H.(H.) jianfengensis sp. nov., H.(H.) liui sp. nov., H.(H.) longiventrius sp. nov., H.(H.) nanlingensis sp. nov., H.(H.) parvus sp. nov., H.(H.) prodigiosus sp. nov., H.(H.) punctatus sp. nov., H.(H.) qingliangensis sp. nov., H.(H.) semidepressus sp. nov., H.(H.) setosiscutum sp. nov., H.(H.) setosus sp. nov., and H.(H.) tenuitergum sp. nov. Seven species of Heterospilus are recorded for China for the first time: H. (Eoheterospilus) rubrocinctus (Ashmead, 1905), H.(H.) alboapicalis Belokobylskij, 1994, H.(H.) ater Fischer, 1960, H.(H.) cephi Rohwer, 1925, H.(H.) kerzhneri Belokobylskij et Maetô, 2009, H.(H.) tauricus Telenga, 1941, and H.(H.) tulyensis Belokobylskij, 1994. Two new synonyms are proposed: H. asiaticola Belokobylskij et Maetô, 2009 with H. chinensis Chen et Shi, 2004 and H. gracilis Shi et Chen with H. separatus Fischer, 1960. A key to the Chinese species of Heterospilus is provided.

Cystic lesions in giant intraventricular meningioma: Two case reports.

RATIONALE: Giant meningioma stemming from the intraventricular zone has been reported to be extremely few. Two cases of supersize (>8 cm) intraventricular meningiomas presenting with cystic lesions and their clinical characteristics were collected in our study. PATIENT CONCERNS: One patient was a 56-year-old man who was hospitalized for blunt headache and weakness of the right lower limb along with a defect of the right visual field for 12 months. The other patient is a 22-year-old lady who presented with a slight headache accompanied by right facial numbness for 1 week. None of them had a significant past medical history. DIAGNOSES: Computed tomography and magnetic resonance imaging of both patients revealed a giant heterogeneous, enhancing tumor mainly in the left trigonum with low-density or hypointense cystic lesions located within or around the tumor. The pathological and immunohistochemical staining indicated fibroblastic meningioma (case 1) and atypical meningioma (case 2) respectively, thus the patients' diagnoses were confirmed. INTERVENTIONS: Total microsurgical resection, including the cystic wall, was performed via a transcortical (transtemporoparietal occipital) approach in both patients, and a ventricular drainage tube was placed for 24 to 48 hours routinely after removed the tumor. OUTCOMES: Postoperatively, both patients recovered free from episodes of symptoms, and imaging examinations confirmed no evidence of regrowth of the meningioma during an average 24 months follow-up. LESSONS: Cystic lesions may indicate the histopathologic malignancy of intraventricular meningioma. Transcortical approach through the posterior temporal lobe or the parieto-occipital lobe is an effective technology for giant intraventricular meningiomas.